Serologicals (NASDAQ:SERO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Serologicals Charts. Click Here for more Serologicals Charts.](/p.php?pid=staticchart&s=N%5ESERO&p=8&t=15)
Serologicals Corporation (NASDAQ: SERO) announced today
that it has completed its previously announced acquisition of Cytomyx
Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc (AIM: CYX).
Based in Cambridge, U.K., Cytomyx Ltd. is a leading provider of ion
channel cell lines and drug discovery services. With 23 distinct ion
channel cell lines commercially available, and more in its pipeline,
Cytomyx Ltd. offers the largest portfolio of distinct ion channel cell
lines in the marketplace today. Serologicals paid U.S. $7 million for
the stock of Cytomyx Ltd.
"We are very pleased to announce the completion of the Cytomyx
Ltd. acquisition," said David A. Dodd, President and CEO of
Serologicals. "Ion channels represent the third largest target class
for Biopharma research and drug development today. The expertise that
Cytomyx Ltd. brings will greatly enhance our drug discovery products
and services portfolio with therapeutically relevant ion channel cell
lines and ion channel screening services. With GPCRs, kinases, and ion
channels, Serologicals will better serve the needs of our Biopharma
customers through a comprehensive portfolio offering."
Additional details about the acquisition and Cytomyx Ltd. business
can be found in the Company's March 14, 2006 press release
(www.serologicals.com) in which the signing of the acquisition
agreement was announced.
Serologicals Corporation, headquartered in Atlanta, Georgia, is a
global provider of biological products and enabling technologies,
which are essential for the research, development and manufacturing of
biologically based life science products. The Company's products and
technologies are used in a wide variety of innovative applications
within the areas of oncology, hematology, immunology, cardiology and
infectious diseases, as well as in the study of molecular biology.
Serologicals has approximately 1,000 employees worldwide, and its
shares are traded on the NASDAQ national stock market under the symbol
SERO.
For information on Serologicals Corporation, visit the company's
corporate website at www.serologicals.com.
This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Words or phrases such as "should result," "are expected to," "we
anticipate," "we estimate," "we project" or similar expressions are
intended to identify forward-looking statements. These statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those expressed in any
forward-looking statements. You should not place undue reliance on
forward-looking statements, since the statements speak only as of the
date that they are made, and Serologicals undertakes no obligation to
update these statements based on events that may occur after the date
of this press release.